28 recruiting, 27 active not recruiting, 18 completed, 13 terminated. 68 Phase 2, 30 Phase 1, 18 Phase 3, 2 Early Phase 1, 1 Phase 4.
Follow this drug Literature Review of isatuximab trials Research Report on isatuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells Isatuximab, VRD - Multiple Myeloma | Phase 2 / Phase 3 | Not yet recruiting | The Affiliated People's Hospital of Ningbo University | 15 | 2027-01-01 | 2026-10-02 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma F182112 Plus Isatuximab and Lenalidomide - Multiple Myeloma (MM), Transplant-eligible Patients | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-10-01 | 2026-09-18 |
| CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia CM336, Isatuximab, Bortezomib - Plasma Cell Leukemia (PCL) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-09-15 | 2026-09-18 |
| CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment CM336 Plus Isatuximab - Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 26 | 2026-09-10 | 2026-09-17 |
| Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma Isatuximab, Iberdomide, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 88 | 2026-09-03 | 2026-09-03 |
| D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM Isatuximab, Iberdomide, Bortezomib (B) - Multiple Myeloma | Phase 3 | Recruiting | Dana-Farber Cancer Institute | 720 | 2026-08-31 | 2026-10-09 |
| Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia Isatuximab - Aplastic Anemia | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2026-06-30 | 2026-09-21 |
| Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT AZD0120, Daratumumab, Dexamethasone - Newly Diagnosed Multiple Myeloma | Phase 3 | Recruiting | AstraZeneca | 750 | 2026-06-26 | 2026-08-14 |
| Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients Isatuximab, Bortezomib, Lenalidomide - Multiple Myeloma | Recruiting | Shanghai Zhongshan Hospital | 333 | 2026-06-01 | 2026-06-23 | |
| Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Selinexor, Carfilzomib, Isatuximab - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Natalie Callander | 62 | 2026-05-21 | 2026-08-31 |
| Horizon Two: HR NDMM (MMRC-100) Bispecific Monoclonal Antibody and Triplet Therapy, Monoclonal Antibody with Stem Cell Transplant - High Risk Newly Diagnosed Multiple Myeloma | Phase 2 | Recruiting | Multiple Myeloma Research Consortium | 300 | 2026-04-30 | 2026-10-02 |
| Isa-VRD in TIE HRMM Isatuximab, bortezomib, lenalidomide, dexamethason, Bortezomib, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 4 | Not yet recruiting | Peking Union Medical College Hospital | 117 | 2026-01-30 | 2026-01-13 |
| Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma Isatuximab - Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Recruiting | University of Utah | 40 | 2025-10-09 | 2026-09-11 |
| ELISA in Relapsed/Refractory MM elranatamab, Isatuximab SC, Isatuximab SC-OBDS - Relapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2025-08-14 | 2026-09-16 |
| Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) Daratumumab, Isatuximab, Bortezomib - De Novo Multiple Myeloma, Anitocabtagene Autoleucel | Phase 2 | Recruiting | PETHEMA Foundation | 30 | 2025-06-30 | 2025-08-01 |
| Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma Isatuximab, Iberdomide, Dexamethasone - Smouldering Myeloma | Phase 2 | Recruiting | University College, London | 63 | 2025-06-02 | 2026-10-20 |
| A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia Randomization + Blinatumomab + chemotherapy, Randomization + Standard frontline T-ALL chemotherapy backbone, Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 1200 | 2025-05-06 | 2026-02-10 |
| A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma Isatuximab SC-OBDS, Montelukast, Dexamethasone - Plasma Cell Myeloma Refractory | Phase 2 | Recruiting | Sanofi | 64 | 2025-03-17 | 2026-02-23 |
| Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients Iberdomide, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Canadian Myeloma Research Group | 75 | 2024-12-12 | 2026-08-31 |
Showing 20 of 101. Sign in to see all of them.
Multiple Myeloma (68) · Neoplasms (7) · Neoplasms, Plasma Cell (6) · Recurrence (5) · Hematologic Neoplasms (4) · Paraproteinemias (4) · Hematologic Diseases (3) · Immunoglobulin Light-chain Amyloidosis (3) · Lymphoma (3) · Renal Insufficiency (3) · Amyloidosis (2) · Blood Protein Disorders (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Plasma Cell (2)
Sanofi (26) · Institute of Hematology & Blood Diseases Hospital, China (4) · Assistance Publique - Hôpitaux de Paris (3) · Massachusetts General Hospital (3) · Medical College of Wisconsin (3) · University of Heidelberg Medical Center (3) · Universitätsklinikum Hamburg-Eppendorf (3) · Canadian Myeloma Research Group (2) · Dana-Farber Cancer Institute (2) · GlaxoSmithKline (2) · Hellenic Society of Hematology (2) · Intergroupe Francophone du Myelome (2) · M.D. Anderson Cancer Center (2) · PETHEMA Foundation (2) · Poitiers University Hospital (2)
United States (59) · France (29) · Spain (21) · Germany (20) · Greece (19) · Italy (19) · Canada (14) · Australia (13) · China (12) · South Korea (12) · Brazil (11) · Czechia (11) · Japan (11) · Sweden (10) · United Kingdom (10)
Binod Dhakal, MD (2) · Evangelos Terpos, Prof (2) · Hartmut Goldschmidt, Prof. (2) · Thomas Martin, MD (2) · Andrew Yee, MD (1) · Anjali Cremer, MD (1) · Cindy Varga, MD (1) · Cliford Mo, MD (1) · Clifton C. Mo, MD (1)
PMID 33980831, PMID 36108425, PMID 38573925, PMID 28483761, PMID 30862646, PMID 31833394, PMID 32409691, PMID 32586908, PMID 32975869, PMID 33080623, PMID 33357481, PMID 33682447, PMID 33730360, PMID 33839618, PMID 34050260, PMID 34097854, PMID 34272304, PMID 34376579, PMID 34732857, PMID 34800109, PMID 34826409, PMID 35058326, PMID 35285981, PMID 35641409, PMID 36239134, PMID 36328040, PMID 36372355, PMID 36433829, PMID 37156782, PMID 37316728, PMID 37479547, PMID 37584290, PMID 37753960, PMID 37990162, PMID 38062124, PMID 38147137, PMID 38299578, PMID 38677302, PMID 38830994, PMID 38832972, PMID 39067465, PMID 39102302, PMID 39134120, PMID 39227452, PMID 39345094, PMID 39528489, PMID 39652594, PMID 39841461, PMID 39865222, PMID 39909655
2023 (9), 2017 (5), 2018 (4), 2016 (2), 2019 (2), 2014 (1), 2025 (1), P30CA138292 (1), U10CA180888 (1)